Advocacy Campaigns
CCA works to advocate for the IBD community in a range of ways:
- Lobbying governments for funding
- Providing submissions about health policy
- Raising consumer needs to researchers and industry
- Awareness campaigns
Current advocacy campaigns
State of the Nation Advocacy
We need your help to secure support from the Australian government to fund the actions specified in the IBD State of The Nation report, which will greatly improve the quality of life for people living with IBD.
Have your say in an important discussion on DNA testing legislation.
Open
Help improve the quality of life for regional Australians living with chronic inflammatory conditions
Closed 2022
Review of the National Medicines Policy
Closed October 2021.
Have your say on PBS listings for IBD Medications
The Pharmaceutical Benefits Advisory Committee (PBAC) is seeking consumer feedback on IBD medications which are being considered for PBS listing. If you would like to provide feedback on a new biologic GUSELKUMAB (Tremfya®) or another biosimilar infusion INFLIXIMAB (Remsima®) then send us an email about what difference it has made/would make to your life to [email protected]. We will then forward all comments consolidated to PBAC. The closing date for comments to CCA is 25 May 2025.
| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |
| GUSELKUMAB Solution for I.V. infusion 200 mg in 20 mL vial Injection 100 mg in 1 mL single use pre-filled pen Injection 200 mg in 2 mL single use pre-filled pen, Injection 100 mg in 1 mL single use pre-filled syringe Injection 200 mg in 2 mL single use pre-filled syringe, Tremfya® JANSSEN-CILAG PTY LTD (New PBS listing) | Severe Crohn disease | To request General Schedule Authority Required (Written) listings for subcutaneous injection and a Section 100 (Highly Specialised Drug Program) Authority Required (Written) listing for I.V. infusion for the treatment of severe Crohn disease. |
| INFLIXIMAB Powder for I.V. infusion 100 mg Remsima® CELLTRION HEALTHCARE AUSTRALIA PTY LTD (New PBS listing) | Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis Severe Crohn disease Complex refractory fistulising Crohn Disease Moderate to severe ulcerative colitis | To request Section 100 (Highly Specialised Drugs Program) Authority Required listings of a new infliximab biosimilar under the same conditions as other biosimilar brands of infliximab. |
For information about the PBS meeting visit the PBAC meeting page on the PBS website.